COMMUNIQUÉS West-GlobeNewswire

Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis
17/12/2018
BEVERLY, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the Company and the U.S. Food and Drug [...]
Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris
17/12/2018
First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials expected to enroll a total of approximately 840 subjects Top-line data anticipated [...]
Saniona’s tesofensine meets primary and secondary endpoints in Phase 3 obesity registration trial
17/12/2018
PRESS RELEASE December 17, 2018 Saniona (OMX: SANION), a biotech company focused on CNS and eating disorders, today announced statistically and clinically significant weight loss for both doses of tesofensine compared [...]
FDA approves Shire’s Motegrity™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC)
17/12/2018
Intended for U.S. Audience FDA approves Shire’s Motegrity ™ (prucalopride), the only serotonin-4 receptor agonist for adults with Chronic Idiopathic Constipation (CIC) Unlike other prescription CIC treatments, Motegrity [...]
Blood donors needed to help patients this holiday season
17/12/2018
OTTAWA, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Canadian Blood Services has called for more than 30,000 blood donors across the country to book and keep their appointments from Dec. 17 to Jan. 6, 2019 to ensure blood and [...]
Les donneurs de sang encouragés à prendre rendez-vous pour aider les patients pendant les Fêtes
17/12/2018
OTTAWA, 17 déc. 2018 (GLOBE NEWSWIRE) -- Ayant besoin de 30 000 donneurs d’ici le 6 janvier, la Société canadienne du sang demande aux gens d’aller donner du sang afin que les patients soignés dans les hôpitaux pendant [...]
Surface Oncology Promotes Jessica Fees to Senior Vice President, Finance and Business Operations
17/12/2018
CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced [...]
Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease
17/12/2018
CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]
Zynerba Pharmaceuticals Provides Clinical Update and Announces Two New Clinical Indications
17/12/2018
- Company Will Focus on Four Childhood Neuropsychiatric Disorders: FXS, DEE, Autism Spectrum Disorder and 22q11.2 Deletion Syndrome - - Cash Runway Now Extends into the Second Half of 2020 - - Conference Call to be Held [...]
TRU NIAGEN® Expands North American Footprint with Product Launch in Canada
17/12/2018
TRU NIAGEN® receives Natural Product Number from Health Canada and is approved for sale in the country to consumers and healthcare practitioners LOS ANGELES, Dec. 17, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: [...]
Ovid Therapeutics Announces Phase 1b/2a Results of OV935/TAK-935 in Adults with Rare Epilepsies
17/12/2018
-- Met primary endpoint of safety and tolerability -- -- A dose-dependent reduction of plasma 24HC levels was observed, consistent with target engagement -- -- Exploratory analysis of clinical activity of OV935 shows a [...]
BeiGene Initiates Two Global Phase 3 Front-Line Clinical Trials of Tislelizumab, in Patients with Gastric Cancer and in Patients with Esophageal Cancer
17/12/2018
CAMBRIDGE, Mass., and BEIJING, China, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Healios Agrees to Make Payment to Extend Exclusive Period for Negotiating an Option for a License to Multistem® Therapy for Indications in China
17/12/2018
Parties working together on development plan in China CLEVELAND, Ohio, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the extension of HEALIOS K.K.’s (Healios) exclusive period to [...]
INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology
17/12/2018
Transformational momentum building as Company plans to apply for two NDAs in 2019 PHOENIX, Dec. 17, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and [...]
Arrayit Corporation Fulfills Clinical Instrumentation Contract with the United States Food and Drug Administration
17/12/2018
Sunnyvale, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ARYC ), a life sciences and personalized medicine company, reports fulfillment of a clinical instrumentation contract with the United States Food [...]
Change to Executive Management – Jakob Gudbrand appointed CEO of GN Hearing
17/12/2018
Today, GN Store Nord announces the appointment of Jakob Gudbrand as CEO of GN Hearing and member of GN Store Nord’s Executive Management, effective as of 18 February 2019. Jakob comes to GN from a position as President [...]
Olainfarm Group Sales in November Grew By 8%
17/12/2018
Preliminary consolidated results of JSC Olainfarm for November 2018 show that total sales of the Group have reached 10.9 million euros, which represents 8% increase compared to the same period of 2018. During the eleven [...]
GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH
17/12/2018
GENFIT: Positive 30-month DSMB Recommendation for Continuation of Phase 3 RESOLVE-IT Study of Elafibranor in NASH Data Safety Monitoring Board (DSMB) recommended the continuation of RESOLVE-IT without any modifications [...]
GENFIT : Issue positive du DSMB à 30 mois, recommandant la poursuite de l'étude clinique de Phase 3 RESOLVE-IT évaluant elafibranor dans la NASH
17/12/2018
GENFIT : Issue positive du DSMB à 30 mois, recommandant la poursuite de l'étude clinique de Phase 3 RESOLVE-IT évaluant elafibranor dans la NASH Le Data Safety Monitoring Board (DSMB) a recommandé la poursuite de l' [...]

Pages